Neuropsychotoxic and neuroprotective potentials of dextromethorphan and its analogs

Journal of Pharmacological Sciences

Volumn 116, Issue 2, 2011, Pages 137-148

  Shin, Eun Joo ^a   Bach, Jae Hyung ^a   Lee, Sung Youl ^a   Kim, Jeong Min ^b   Lee, Jinhwa ^b   Hong, Jau Shyong ^c   Nabeshima, Toshitaka ^d   Kim, Hyoung Chun ^a  

^a Kangwon National University   (South Korea)

^b Green Cross Company   (South Korea)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d MEIJO UNIVERSITY   (Japan)

Author keywords

3 Hydroxymorphinan; Dextromethorphan; Dimemorfan; Neurodegenerative disorder; Neuroprotection; Neuropsychotoxicity

Indexed keywords

CODEINE; DEXTROMETHORPHAN; DEXTRORPHAN; DIMEMORFAN; DIZOCILPINE; GCC 1290K; MORPHINAN DERIVATIVE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINE; NORLEVORPHANOL; PRODRUG; QUINIDINE; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANTICONVULSANT ACTIVITY; BRAIN INFARCTION; BRAIN ISCHEMIA; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERANCE; HUMAN; MENTAL INSTABILITY; NERVE DEGENERATION; NEUROPROTECTION; NEUROPSYCHOTOXICITY; NEUROTOXICITY; NOCICEPTION; NONHUMAN; PAIN; PARKINSON DISEASE; PROTEIN SYNTHESIS INHIBITION; REPERFUSION INJURY; REVIEW; RISK BENEFIT ANALYSIS; TOXICITY TESTING; UNSPECIFIED SIDE EFFECT;

EID: 79959347631     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11R02CR     Document Type: Review

References (100)

1. Bem JL, Peck R. Dextromethorphan. An overview of safety issues. Drug Saf. 1992;7:190-199.
2. Desai S, Aldea D, Daneels E, Soliman M, Braksmajer AS, Kopes-Kerr CP. Chronic addiction to dextromethorphan cough syrup: a case report. J Am Board Fam Med. 2006;19:320-323. (Pubitemid 43822161)
3. Wolfe TR, Caravati EM. Massive dextromethorphan ingestion and abuse. Am J Emerg Med. 1995;13:174-176.
4. Chung H, Park M, Hahn E, Choi H, Lim M. Recent trends of drug abuse and drug-associated deaths in Korea. Ann N Y Acad Sci. 2004;1025:458-464. (Pubitemid 39643894)
5. Cranston JW, Yoast R. Abuse of dextromethorphan. Arch Fam Med. 1999;8:99-100.
6. Hollander D, Pradas J, Kaplan R, McLeod HL, Evans WE, Munsat TL. High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. Ann Neurol. 1994;36:920-924. (Pubitemid 24370934)
7. Pender ES, Parks BR. Toxicity with dextromethorphan- containing preparations: a literature review and report of two additional cases. Pediatr Emerg Care. 1991;7:163-165.
8. Wu D, Otton SV, Kalow W, Sellers EM. Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. J Pharmacol Exp Ther. 1995;274:1431-1437.
9. Tortella FC, Pellicano M, Bowery NG. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci. 1989;10:501-507. (Pubitemid 19285630)
10. Holtzman SG. Phencyclidine-like discriminative effects of opioids in the rat. J Pharmacol Exp Ther. 1980;214:614-619. (Pubitemid 10061409)
11. Kim HC, Jhoo WK. Alterations in motor activity induced by high dose oral administration of dextromethorphan throughout two consecutive generations in mice. Arch Pharm Res. 1995;18:146-152.
12. Kim HC, Jhoo WK, Kwon MS, Hong JS. Effects of chronic dextromethorphan administration on the cellular immune responses in mice. Arch Pharm Res. 1995;18:267-270.
13. Holtzman SG. Discriminative stimulus effects of dextromethorphan in the rat. Psychopharmacology (Berl). 1994;116:249-254. (Pubitemid 24345273)
14. Herling S, Solomon RE, Woods JH. Discriminative stimulus effects of dextrorphan in pigeons. J Pharmacol Exp Ther. 1983;227:723-731. (Pubitemid 14215059)
15. Glick SD, Maisonneuve IM, Dickinson HA, Kitchen BA. Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats. Eur J Pharmacol. 2001;422:87-90. (Pubitemid 32595579)
16. Yang PP, Huang EY, Yeh GC, Tao PL. Co-administration of dextromethorphan with methamphetamine attenuates methamphetamine- induced rewarding and behavioral sensitization. J Biomed Sci. 2006;13:695-702. (Pubitemid 44496870)
17. Pulvirenti L, Balducci C, Koob GF. Dextromethorphan reduces intravenous cocaine self-administration in the rat. Eur J Pharmacol. 1997;321:279-283. (Pubitemid 27105929)
18. Kim HC, Park BK, Hong SY, Jhoo WK. Dextromethorphan alters the reinforcing effect of cocaine in the rat. Methods Find Exp Clin Pharmacol. 1997;19:627-631.
19. Jhoo WK, Shin EJ, Lee YH, Cheon MA, Oh KW, Kang SY, et al. Dual effects of dextromethorphan on cocaine-induced conditioned place preference in mice. Neurosci Lett. 2000;288:76-80.
20. Kim HC, Bing G, Shin EJ, Jhoo HS, Cheon MA, Lee SH, et al. Dextromethorphan affects cocaine-mediated behavioral pattern in parallel with a long-lasting Fos-related antigen-immunoreactivity. Life Sci. 2001;69:615-624. (Pubitemid 32673620)
21. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360-1362. (Pubitemid 19170513)
22. Sharp FR, Butman M, Aardalen K, Nickolenko J, Nakki R, Massa SM, et al. Neuronal injury produced by NMDA antagonists can be detected using heat shock proteins and can be blocked with antipsychotics. Psychopharmacol Bull. 1994;30:555-560.
23. Hashimoto K, Tomitaka S, Narita N, Minabe Y, Iyo M, Fukui S. Induction of heat shock protein (HSP)-70 in posterior cingulate and retrosplenial cortex of rat brain by dizocilpine and phencyclidine: lack of protective effects of sigma receptor ligands. Addict Biol. 1996;1:61-70. (Pubitemid 126683418)
24. Carliss RD, Radovsky A, Chengelis CP, O'Neill TP, Shuey DL. Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain. NeuroToxicology. 2007;28:813-818. (Pubitemid 47058577)
25. Cotman CW, Iversen LL. Excitatory amino acids in the brain - focus on NMDA receptors. Trends Neurosci. 1987;10:263-265.
26. Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 1986;319:774-776.
27. Malenfant SA, O'Hearn S, Fleming AS. MK801, an NMDA antagonist, blocks acquisition of a spatial task but does not block maternal experience effects. Physiol Behav. 1991;49:1129-1137.
28. Krug M, Matthies R, Wagner M, Brodemann R. Non-opioid antitussives and methadone differentially influence hippocampal long-term potentiation in freely moving rats. Eur J Pharmacol. 1993;231:355-361. (Pubitemid 23056968)
29. Murata S, Kawasaki K. Common and uncommon behavioural effects of antagonists for different modulatory sites in the NMDA receptor/channel complex. Eur J Pharmacol. 1993;239:9-15. (Pubitemid 23240134)
30. Sierocinska J, Nikolaev E, Danysz W, Kaczmarek L. Dextrorphan blocks long- but not short-term memory in a passive avoidance task in rats. Eur J Pharmacol. 1991;205:109-111.
31. Bane A, Rojas D, Indermaur K, Bennett T, Avery D. Adverse effects of dextromethorphan on the spatial learning of rats in the Morris water maze. Eur J Pharmacol. 1996;302:7-12. (Pubitemid 26179924)
32. Dematteis M, Lallement G, Mallaret M. Dextromethorphan and dextrorphan in rats: common antitussives - different behavioural profiles. Fundam Clin Pharmacol. 1998;12:526-537. (Pubitemid 29166497)
33. Hinsberger A, Sharma V, Mazmanian D. Cognitive deterioration from long-term abuse of dextromethorphan: a case report. J Psychiatry Neurosci. 1994;19:375-377. (Pubitemid 24352712)
34. Kim HC, Shin CY, Seo DO, Jhoo JH, Jhoo WK, Kim WK, et al. New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice. Life Sci. 2003;72:1883-1895. (Pubitemid 36174024)
35. Tortella FC, Musacchio JM. Dextromethorphan and carbetapentane: centrally acting non-opioid antitussive agents with novel anticonvulsant properties. Brain Res. 1986;383:314-318. (Pubitemid 17179988)
36. Ferkany JW, Borosky SA, Clissold DB, Pontecorvo MJ. Dextromethorphan inhibits NMDA-induced convulsions. Eur J Pharmacol. 1988;151:151-154.
37. Leander JD. Evaluation of dextromethorphan and carbetapentane as anticonvulsants and N-methyl-D-aspartic acid antagonists in mice. Epilepsy Res. 1989;4:28-33. (Pubitemid 19165867)
38. Feeser HR, Kadis JL, Prince DA. Dextromethorphan, a common antitussive, reduces kindled amygdala seizures in the rat. Neurosci Lett. 1988;86:340-345. (Pubitemid 18079155)
39. Takazawa A, Anderson P, Abraham WC. Effects of dextromethorphan, a nonopioid antitussive, on development and expression of amygdaloid kindled seizures. Epilepsia. 1990;31:496-502. (Pubitemid 20310807)
40. Kim HC, Pennypacker KR, Bing G, Bronstein D, McMillian MK, Hong JS. The effects of dextromethorphan on kainic acidinduced seizures in the rat. NeuroToxicology. 1996;17:375-385.
41. Kim HC, Suh HW, Bronstein D, Bing G, Wilson B, Hong JS. Dextromethorphan blocks opioid peptide gene expression in the rat hippocampus induced by kainic acid. Neuropeptides. 1997;31:105-112. (Pubitemid 27240049)
42. Kim HC, Ko KH, Kim WK, Shin EJ, Kang KS, Shin CY, et al. Effects of dextromethorphan on the seizures induced by kainate and the calcium channel agonist BAY k-8644: comparison with the effects of dextrorphan. Behav Brain Res. 2001;120:169-175. (Pubitemid 32140984)
43. Shin EJ, Nabeshima T, Lee PH, Kim WK, Ko KH, Jhoo JH, et al. Dimemorfan prevents seizures induced by the L-type calcium channel activator BAY k-8644 in mice. Behav Brain Res. 2004;151:267-276. (Pubitemid 38501449)
44. Shin EJ, Nah SY, Chae JS, Bing G, Shin SW, Yen TP, et al. Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats. Neurochem Int. 2007;50:791-799. (Pubitemid 46710192)
45. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev. 1990;42:223-286. (Pubitemid 20291784)
46. Kim HC, Bing G, Jhoo WK, Kim WK, Shin EJ, Im DH, et al. Metabolism to dextrorphan is not essential for dextromethorphan's anticonvulsant activity against kainate in mice. Life Sci. 2003;72:769-783. (Pubitemid 35449504)
47. Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman RB, et al. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci. 1992;13:85-86.
48. Aram JA, Martin D, Tomczyk M, Zeman S, Millar J, Pohler G, et al. Neocortical epileptogenesis in vitro: studies with N-methyl- D-aspartate, phencyclidine, sigma and dextromethorphan receptor ligands. J Pharmacol Exp Ther. 1989;248:320-328. (Pubitemid 19063508)
49. Kim HC, Bing G, Jhoo WK, Ko KH, Kim WK, Lee DC, et al. Dextromethorphan modulates the AP-1 DNA-binding activity induced by kainic acid. Brain Res. 1999;824:125-132. (Pubitemid 29222894)
50. Mendelsohn LG, Kerchner GA, Kalra V, Zimmerman DM, Leander JD. Phencyclidine receptors in rat brain cortex. Biochem Pharmacol. 1984;33:3529-3535. (Pubitemid 15220926)
51. Cole AE, Eccles CU, Aryanpur JJ, Fisher RS. Selective depression of N-methyl-D-aspartate-mediated responses by dextrorphan in the hippocampal slice in rat. Neuropharmacology. 1989;28:249-254. (Pubitemid 19078886)
52. Le Gal La Salle G, Calvino B, Ben-Ari Y. Morphine enhances amygdaloid seizures and increases inter-ictal spike frequency in kindled rats. Neurosci Lett. 1977;6:255-260. (Pubitemid 8238503)
53. Echevarria E, Robles L, Tortella FC. Differential profiles of putative dextromrthorphan sigma ligands in experimental seizure models. FASEB J. 1990;4:A331.
54. Netzer R, Pflimlin P, Trube G. Dextromethorphan blocks Nmethyl- D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur J Pharmacol. 1993;238:209-216. (Pubitemid 23214433)
55. Shin EJ, Nah SY, Kim WK, Ko KH, Jhoo WK, Lim YK, et al. The dextromethorphan analog dimemorfan attenuates kainateinduced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan. Br J Pharmacol. 2005;144:908-918. (Pubitemid 40593016)
56. Zhou GZ, Musacchio JM. Computer-assisted modeling of multiple dextromethorphan and sigma binding sites in guinea pig brain. Eur J Pharmacol. 1991;206:261-269.
57. Franklin PH, Murray TF. Identification and initial characterization of high-affinity [3H]dextrorphan binding sites in rat brain. Eur J Pharmacol. 1990;189:89-93. (Pubitemid 20253000)
58. Loscher W, Honack D. Responses to NMDA receptor antagonists altered by epileptogenesis. Trends Pharmacol Sci. 1991;12:52.
59. Choi DW. Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res. 1987;403:333-336. (Pubitemid 17019714)
60. George CP, Goldberg MP, Choi DW, Steinberg GK. Dextromethorphan reduces neocortical ischemic neuronal damage in vivo. Brain Res. 1988;440:375-379. (Pubitemid 18049238)
61. Klette KL, DeCoster MA, Moreton JE, Tortella FC. Role of calcium in sigma-mediated neuroprotection in rat primary cortical neurons. Brain Res. 1995;704:31-41.
62. Britton P, Lu XC, Laskosky MS, Tortella FC. Dextromethorphan protects against cerebral injury following transient, but not permanent, focal ischemia in rats. Life Sci. 1997;60:1729-1740. (Pubitemid 27225902)
63. Bokesch PM, Marchand JE, Connelly CS, Wurm WH, Kream RM. Dextromethorphan inhibits ischemia-induced c-fos expression and delayed neuronal death in hippocampal neurons. Anesthesiology. 1994;81:470-477. (Pubitemid 24320639)
64. Luhmann HJ, Scheid M. Dextromethorphan attenuates hypoxiainduced neuronal dysfunction in rat neocortical slices. Neurosci Lett. 1994;178:171-174. (Pubitemid 24274389)
65. Monyer H, Choi DW. Morphinans attenuate cortical neuronal injury induced by glucose deprivation in vitro. Brain Res. 1988;446:144-148. (Pubitemid 18091756)
66. Gao HM, Liu B, Zhang W, Hong JS. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 2003;17:1954-1956.
67. Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, et al. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J. 2004;18:589-591.
68. Vaglini F, Pardini C, Bonuccelli U, Maggio R, Corsini GU. Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice. Brain Res. 2003;973:298-302.
69. Scotti de Carolis A, Popoli P, Pezzola A, Sagratella S. Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist. Arch Int Pharmacodyn Ther. 1991;310:132-141.
70. Kaur S, Starr MS. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Eur J Pharmacol. 1995;280:159-166.
71. Bonuccelli U, Del Dotto P, Piccini P, Behge F, Corsini GU, Muratorio A. Dextromethorphan and parkinsonism. Lancet. 1992;340:53.
72. Montastruc JL, Fabre N, Rascol O, Senard JM, Blin O. N-methyl- D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan. Mov Disord. 1994;9:242-243. (Pubitemid 24092351)
73. Arciniegas DB, Topkoff J. The neuropsychiatry of pathologic affect: an approach to evaluation and treatment. Semin Clin Neuropsychiatry. 2000;5:290-306.
74. 3H]3-(-3- hydroxyphenyl)-N-(1-propyl)piperidine. Mol Pharmacol. 1989;35:1-5.
75. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets. 2001;2:241-271. (Pubitemid 32821469)
76. Steinberg GK, Bell TE, Yenari MA. Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. J Neurosurg. 1996;84:860-866. (Pubitemid 26120608)
77. Inaba T, Tyndale RE, Mahon WA. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. Br J Clin Pharmacol. 1986;22:199-200.
78. Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ, Sellers EM. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol. 2004;44:1132-1142. (Pubitemid 39202458)
79. Wilson SAK. Some problems in neurology. J Neurol Psychopathol. 1924;4:299-333.
80. Miller A, Panitch H. Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect. J Neurol Sci. 2007;259:67-73. (Pubitemid 47039242)
81. Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68:693-702.
82. Aanonsen LM, Wilcox GL. Nociceptive action of excitatory amino acids in the mouse: effects of spinally administered opioids, phencyclidine and sigma agonists. J Pharmacol Exp Ther. 1987;243:9-19. (Pubitemid 17162692)
83. Battaglia G, Rustioni A. Coexistence of glutamate and substance P in dorsal root ganglion neurons of the rat and monkey. J Comp Neurol. 1988;277:302-312. (Pubitemid 19002137)
84. Weinbroum AA, Rudick V, Paret G, Ben-Abraham R. The role of dextromethorphan in pain control. Can J Anaesth. 2000;47:585-596.
85. Woolf CJ, Chong MS. Preemptive analgesia - treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg. 1993;77:362-379. (Pubitemid 23221440)
86. Church J, Lodge D, Berry SC. Differential effects of dextrorphan and levorphanol on the excitation of rat spinal neurons by amino acids. Eur J Pharmacol. 1985;111:185-190. (Pubitemid 15086818)
87. 2+ concentration. Neurosci Lett. 1991;124:232-234.
88. Kawamata T, Omote K, Kawamata M, Namiki A. Premedication with oral dextromethorphan reduces postoperative pain after tonsillectomy. Anesth Analg. 1998;86:594-597. (Pubitemid 28119429)
89. Ida H. The nonnarcotic antitussive drug dimemorfan: a review. Clin Ther. 1997;19:215-231. (Pubitemid 27239640)
90. Kase Y, Kito G, Miyata T, Uno T, Takahama K, Ida H. Antitussive activity and other related pharmacological properties of d-3-methyl-N-methylmorphinan (AT-17). Arzneimittelforschung. 1976;26:353-360.
91. Chou YC, Liao JF, Chang WY, Lin MF, Chen CF. Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res. 1999;821:516-519.
92. Wang HH, Chien JW, Chou YC, Liao JF, Chen CF. Anti-amnesic effect of dimemorfan in mice. Br J Pharmacol. 2003;138:941-949.
93. Wang HH, Chou YC, Liao JF, Chen CF. Dimemorfan enhances acetylcholine release from rat hippocampal slices. Brain Res. 2004;1008:113-115.
94. Shen YC, Wang YH, Chou YC, Liou KT, Yen JC, Wang WY, et al. Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation. J Neurochem. 2008;104:558-572.
95. Wang YH, Shen YC, Liao JF, Lee CH, Chou CY, Liou KT, et al. Anti-inflammatory effects of dimemorfan on inflammatory cells and LPS-induced endotoxin shock in mice. Br J Pharmacol. 2008;154:1327-1338.
96. Zapata A, Gasior M, Geter-Douglass B, Tortella FC, Newman AH, Witkin JM. Attenuation of the stimulant and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-alkoxy derivatives of dextromethorphan. Pharmacol Biochem Behav. 2003;74:313-323. (Pubitemid 35449516)
97. Shin EJ, Lee PH, Kim HJ, Nabeshima T, Kim HC. Neuropsychotoxicity of abused drugs: potential of dextromethorphan and novel neuroprotective analogs of dextromethorphan with improved safety profiles in terms of abuse and neuroprotective effects. J Pharmacol Sci. 2008;106:22-27. (Pubitemid 351159065)
98. Zhang W, Shin EJ, Wang T, Lee PH, Pang H, Wie MB, et al. 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. FASEB J. 2006;20:2496-2511. (Pubitemid 44953822)
99. Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, et al. 3- hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J. 2005;19:395-397. (Pubitemid 40316528)
100. Du C, Hu R, Hsu CY, Choi DW. Dextromethorphan reduces infarct volume, vascular injury, and brain edema after ischemic brain injury. J Neurotrauma. 1996;13:215-222. (Pubitemid 26142614)